Impetigo: Diagnosis, Treatment & Prevention

Impetigo is a superficial bacterial infection of the epidermis. The skin barrier—either intact in primary disease or already broken in secondary disease (insect bite, abrasion, atopic dermatitis flare, scabies excoriation, varicella crust)—is colonised by Staphylococcus aureus alone, by group A beta-haemolytic Streptococcus pyogenes alone, or by both organisms together. Bacterial adherence to fibronectin receptors exposed by trauma, plus a humid micro-environment, allows rapid local spread; nonbullous lesions evolve from a vesicle or pustule to a thin-roofed pustule that ruptures, leaving the characteristic golden-yellow crust over a moist erythematous base. In bullous disease, exfoliative toxins A and B from a phage group II S. aureus strain cleave desmoglein-1 in the granular layer to produce flaccid superficial bullae without surrounding cellulitis, classically on the trunk and intertriginous areas of infants.

Most cases are children, but adults can develop impetigo at sites of skin trauma—shaving cuts, contact-sport abrasions, occupational hand work, post-surgical wounds, and on top of chronic dermatitis. The natural history without treatment is short and self-limiting in most immunocompetent hosts (resolving in 7–21 days), with the trade-off being weeks of contagiousness, autoinoculation to other body sites, and a small but real risk of post-streptococcal glomerulonephritis from nephritogenic GAS strains. Antibiotic treatment shortens the contagious window, reduces autoinoculation and household spread, and accelerates symptomatic clearance, which is the dominant reason to treat rather than watch.

Clinically, the literature distinguishes three forms: nonbullous impetigo (~70% of paediatric cases, the classic honey-crusted plaques), bullous impetigo (almost exclusively staphylococcal, more systemic features), and ecthyma (a deep ulcerative form that penetrates the dermis, leaving punched-out ulcers that scar). The framework matters because it changes the antibiotic ladder, the likelihood of bacteraemia, and the surveillance plan after the lesion has cleared.

Bedside language often compresses every crusted lesion into the single label “impetigo”, but management splits sharply by depth, extent and host factors. Mapping the patient onto a clear subtype takes ten seconds and prevents both unnecessary oral antibiotics for a single localised lesion and dangerous undertreatment of ecthyma or invasive disease in an immunocompromised host.

↔On a small screen, swipe or scroll sideways to see the full table.

Two pitfalls deserve flagging early. First, repeated topical mupirocin for "impetigo" that is actually recurrent eczema with secondary infection wastes antibiotic stewardship and misses the underlying barrier disease—treat the dermatitis with appropriate topical steroid (for example a high-potency steroid only as guided) and emollients alongside the antimicrobial. Second, "impetigo" that does not respond to a sensible topical course in 5–7 days is rarely just resistance—it is usually the wrong diagnosis (HSV, eczema herpeticum, tinea, contact dermatitis, scabies) and needs reassessment before therapy is escalated.

Most patients walk into clinic or the emergency department with a recognisable lesion picture rather than a systemic complaint, and the diagnosis is overwhelmingly clinical. Nursing assessments that consciously document the pattern, distribution, depth and number of lesions catch atypical disease (deep ecthyma, eczema herpeticum, varicella) and guide both treatment and infection control more reliably than a single "skin infection" entry.

Nonbullous impetigo

• Initial papule or vesicle on a red base, evolving over hours to a thin-roofed pustule that ruptures and leaves an oozing erosion.
• Adherent honey-coloured (golden-yellow) crust over the erosion, sometimes described as "cornflakes stuck to the skin"—classic but not pathognomonic.
• Distribution favours face (perinasal, perioral), hands, forearms and lower limbs; trunk lesions are more common in bullous disease.
• Mild itch and burning are typical; pain is uncommon unless lesions are deep or extensive—a painful, rapidly enlarging lesion should redirect thinking to deeper infection or HSV.
• Mild regional lymphadenopathy in roughly a third of children; systemic features (fever, malaise) are uncommon.
• Crusted rash may be the only complaint; document itch intensity and any sleep disruption to gauge severity.

Bullous impetigo

• Larger, flaccid, fluid-filled bullae arising on apparently intact skin; trunk and intertriginous regions overrepresented.
• Bullae rupture easily, leaving a moist erythematous base with a fine peripheral collarette of scale—no thick honey crust.
• Lesions are fewer than in nonbullous disease but each is larger; intraoral involvement is possible, unlike nonbullous disease.
• Low-grade fever, irritability and reduced feeding can appear in infants—lower the threshold for admission and infectious-disease input.
• Beware widespread denudation suggestive of staphylococcal scalded skin syndrome (SSSS) in neonates and very young infants; perioral fissuring, Nikolsky-positive skin and systemic features distinguish SSSS from localised bullous disease.

Ecthyma

• Deep, punched-out ulcer with violaceous border and adherent yellow-grey crust; localised swelling and tenderness are typical.
• Lower legs and feet predominate, often after insect bites, neglected skin trauma or overlying tinea.
• Heals with scarring; predisposing factors (poor hygiene, malnutrition, immunosuppression, diabetes, IVDU) should be recorded and addressed.

Atypical presentations to watch for

• Recurrent or refractory disease in an adult—screen for diabetes, HIV, biologic therapy and hidden chronic dermatosis.
• Outbreak clusters in schools, military settings, contact sports or homeless services—coordinate with public health teams and consider community MRSA.
• Periauricular, intranasal or umbilical lesions in neonates—lower threshold for systemic antibiotics and admission for observation.
• Sudden expansion of erythema beyond the plaque, induration, lymphangitic streak or constitutional features—reclassify towards invasive infection or sepsis rather than treating as ordinary impetigo.

Aetiology shapes both empirical antibiotic choice and the surveillance plan. Staphylococcus aureus dominates nonbullous and bullous disease in iodine-replete, high-resource settings; group A streptococcus contributes a meaningful share of nonbullous disease in tropical and resource-limited settings, and remains relevant everywhere because of its post-infectious complications. MRSA must be in the differential whenever local prevalence is high, the patient has had recent antibiotics, healthcare exposure, contact sport or institutional crowding, or when therapy fails.

Microbiology

• Nonbullous impetigo: ~80% pure S. aureus; ~10% pure GAS; ~10% mixed. Phage groups vary geographically; nephritogenic GAS strains underlie post-streptococcal glomerulonephritis.
• Bullous impetigo: almost exclusively S. aureus, mediated by exfoliative toxins A and B that target desmoglein-1.
• Ecthyma: usually GAS, sometimes with S. aureus co-infection; gram-negative organisms appear in immunocompromised hosts and in pseudomonal "ecthyma gangrenosum"—a different entity that demands urgent broad cover.
• MRSA: community-acquired strains (often USA300 in North America) carry Panton-Valentine leukocidin (PVL) genes and present with recurrent furunculosis and abscesses as much as classic impetigo; treat by culture-led therapy.

Modifiable risk factors

• Skin barrier disruption: atopic dermatitis flares, chronic dry skin, scabies, head lice, insect bites, varicella, contact dermatitis, abrasions and shaving cuts.
• Crowded living: childcare, military barracks, prisons, contact sports (wrestling, rugby), homeless services, sports gyms and locker rooms.
• Hot, humid climate; sweat and occluded clothing accelerate colonisation and lesion spread.
• Poor hand and skin hygiene access; shared towels, razors and bedding within households.
• Antibiotic exposure within the last 6–12 months, healthcare contact or known MRSA carriage in the household.

Host factors that change management

• Age extremes: neonates (risk of staphylococcal scalded skin syndrome and sepsis) and frail older adults with multimorbidity.
• Diabetes mellitus (type 2 and type 1), end-stage renal disease, peripheral vascular disease.
• Immunosuppression: chemotherapy, biologics (TNF inhibitors, JAK inhibitors), transplant medication, HIV with low CD4, malnutrition.
• Pregnancy—prefer mupirocin or hydrogen peroxide topically; cephalexin and flucloxacillin remain safe oral options when needed.
• Concurrent ear-, nose- and throat infection or a household pharyngitis case—screen for active GAS pharyngitis to coordinate the antibiotic plan.

Impetigo is a clinical diagnosis. The lesion morphology, distribution and patient story carry the work, and routine swabs are not needed for typical localised disease. Reserve laboratory work for atypical presentations, treatment failure, suspected MRSA, ecthyma, recurrence, neonates and outbreak settings.

Bedside assessment

• Targeted history: onset, duration, prior episodes, household contacts, school exclusion concerns, recent skin trauma, contact-sport or institutional exposure, allergies, previous antibiotic courses, atopic dermatitis or scabies.
• Structured skin assessment covering pattern, lesion count, depth (superficial vs ulcerative), distribution, regional lymphadenopathy and any cellulitic spread.
• Photograph the lesion margin (where local policy permits) and mark expansion in the chart so that any clinician at the next contact can see whether the lesion is improving.
• Vital signs at every encounter via routine vital sign measurement—new fever, tachycardia, lymphangitis or hypotension reclassifies the case as systemic.

When to swab

• Suspected MRSA (failed first-line therapy, household carrier, sports cluster, healthcare exposure).
• Atypical or refractory lesion not responding to a 5–7 day topical course.
• Bullous impetigo with extensive denudation, ecthyma, or recurrence.
• Outbreaks in schools, daycare, contact sports, dialysis units, prisons or military settings.
• Immunocompromise, neonates and patients with prosthetic devices.

Send a wound swab from de-roofed lesion exudate using sterile specimen collection; chart the antimicrobial allergies so the laboratory can flag relevant sensitivities. Skin biopsy is not routine but may be considered in refractory or atypical disease via skin biopsy to exclude bullous pemphigoid, pemphigus or fungal mimics.

Bloods and adjuncts

• Routine bloods are unnecessary for typical localised disease.
• Blood cultures, full blood count, CRP and renal function are appropriate for febrile bullous disease, suspected SSSS, ecthyma with systemic features, neonates, and any concern for sepsis—couple with bedside sepsis screening.
• HSV PCR from a vesicle base when eczema herpeticum is on the differential.
• Anti-streptolysin O is not a tool to confirm impetigo but may help when post-streptococcal glomerulonephritis is suspected—anti-DNase B is more reliable after skin GAS than ASO.
• Consider HIV testing in a previously healthy adult who develops bullous impetigo or has recurrent severe staphylococcal disease.

The pragmatic chain that primary-care, school-health and ward teams can run from a single clinic encounter:

1. Confirm the pattern. Honey-crusted plaques, flaccid bullae or punched-out ulcers? Localised or extensive? Any lymphadenopathy or systemic features?
2. Risk-stratify the host. Neonate, infant, immunocompromised, diabetic, post-surgical, sports cluster or household outbreak? Each pushes the threshold for systemic antibiotics and culture lower.
3. Decide topical or oral. Localised non-bullous disease with <5 lesions and one body area in an immunocompetent child—topical hydrogen peroxide 1% (NICE first line in localised disease) or mupirocin 2% three times daily for 5 days. Anything beyond that—oral cephalexin or flucloxacillin for 7 days, with MRSA-active alternatives where indicated.
4. Swab when in doubt. MRSA suspected, refractory, recurrent, ecthyma, bullous, immunocompromise, neonate or outbreak.
5. Lock in infection control. Cover the lesions; reinforce hand hygiene; separate towels, bedding, and razors; exclude from school, daycare, gym and contact sport for at least 24–48 hours after antibiotics start, or until lesions are fully crusted if no antibiotics are used.
6. Plan the follow-up. Reassess at day 5–7. Improving—complete the course, document resolution, and lift restrictions. Static or worse—reassess the diagnosis, send a swab if not yet done, and step up therapy. Recurrent—screen for skin barrier disease, scabies, household carriage and consider 5 days of decolonisation.
7. Surveil for late complications. Document baseline blood pressure and dipstick urinalysis at follow-up in patients with extensive GAS-associated impetigo, particularly during community outbreaks.

Several conditions resemble impetigo at the bedside, and a number of them are higher-stakes if mistreated. The table below is built for triage rather than encyclopaedic coverage.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy aims to shorten the contagious window, reduce spread, prevent autoinoculation and accelerate symptomatic clearance. Almost all immunocompetent patients can be treated as outpatients. Decision points are: localised vs extensive, bullous vs non-bullous, MRSA risk, allergies, age, pregnancy, and previous courses.

Topical first-line for localised non-bullous disease

• Hydrogen peroxide 1% cream applied two to three times daily for 5 days—NICE first-line for localised non-bullous impetigo in immunocompetent patients to reduce antimicrobial selection pressure; clean off crusts gently before each application.
• Mupirocin 2% ointment applied three times daily for 5 days—dominant North American first-line; effective against most S. aureus and GAS strains; rising resistance reported in some populations.
• Fusidic acid 2% cream three times daily for 5 days where local resistance is <10% (UK, Europe, Australia). High resistance rates in some US settings limit usefulness.
• Retapamulin 1% ointment twice daily for 5 days where licensed; useful when mupirocin resistance is suspected.
• Ozenoxacin 1% cream twice daily for 5 days where licensed (US, EU, Australia)—covers methicillin-sensitive and -resistant S. aureus and is helpful for paediatric use.

Oral therapy

Move to oral antibiotics when there are five or more lesions, multiple body sites, deep or bullous lesions, regional lymphadenopathy, systemic features, immunosuppression, neonates, or after a 5–7 day topical failure. The empirical agent must cover both S. aureus and group A streptococcus.

• First-line (most pathways): oral cephalexin 25–50 mg/kg/day in 2–4 divided doses (paediatric) or 250–500 mg QID (adult) for 7 days; flucloxacillin or dicloxacillin where used locally.
• True penicillin allergy: oral clindamycin 10–25 mg/kg/day divided 6–8 hourly (paediatric) or 300–450 mg QID (adult) for 7 days; macrolides such as erythromycin only where local resistance is low.
• MRSA suspected or confirmed: clindamycin (if D-test negative), doxycycline in patients >8 years and outside pregnancy, or trimethoprim-sulfamethoxazole; do not use trimethoprim-sulfamethoxazole alone if pure GAS is suspected because GAS coverage is unreliable—pair with an anti-streptococcal agent or culture-confirm.
• Pure streptococcal disease (culture confirmed): oral penicillin V or amoxicillin are appropriate first-line.
• IV therapy: reserved for SSSS, neonatal disease, sepsis, ecthyma with systemic features and treatment failure—follow local antimicrobial guidance for IV cefazolin, flucloxacillin, vancomycin or linezolid as indicated.

Adjuncts

• Soak crusts off with warm tap water and a clean cloth before applying topical therapy—improves drug penetration and reduces autoinoculation.
• Cover lesions with a clean, breathable dressing where the site allows; teach the patient or carer to use disposable gloves and discard with confidence.
• Symptom relief: simple analgesia (acetaminophen / ibuprofen weight-based) and a short antihistamine for sleep-disturbing itch can be reasonable; no role for routine antiseptic soaks beyond standard hygiene.
• Treat the underlying skin barrier disease—atopic dermatitis with emollients and appropriate steroid potency, scabies and lice with their specific therapy—otherwise impetigo will recur within weeks.

What not to do

• Do not co-prescribe topical and oral antibiotics for the same uncomplicated lesion—it adds resistance pressure without clinical benefit.
• Do not extend therapy past 5–7 days "to be safe"—if lesions are not improving, reassess the diagnosis and culture rather than extend.
• Do not use topical antibiotics for prolonged decolonisation in the community without a clear indication; reserve nasal mupirocin for confirmed recurrent disease or culture-positive household carriers.
• Do not omit the infection-control conversation: the antibiotic course is half the treatment; covering lesions, hand hygiene and laundering the rest.

Neonates and young infants

Lower the threshold for admission, blood cultures and IV antibiotics. Bullous disease in this group can rapidly evolve into staphylococcal scalded skin syndrome. Avoid topical-only therapy in infants under 2 months unless under specialist guidance, and involve paediatric infectious-disease teams early.

Pregnancy and breastfeeding

Topical mupirocin and 1% hydrogen peroxide are widely accepted in pregnancy. Oral cephalexin or amoxicillin-clavulanate are preferred when systemic therapy is needed. Flucloxacillin is acceptable in many UK pathways. Avoid doxycycline and sulfa drugs in late pregnancy; use clindamycin where MRSA cover is needed. For breastfeeding parents with peri-areolar lesions, treat alongside the infant if the infant is clinically affected, and continue feeding from the unaffected breast where feasible.

Older adults and frail patients

Frailty, multimorbidity and polypharmacy raise the risk of systemic spread. Account for renal function in dosing, screen for diabetes, peripheral vascular disease and chronic skin conditions. Document falls risk and ability to apply topical therapy independently—failure to apply is a common "treatment failure".

Immunocompromised hosts

Children on biologics, transplant recipients, those on chemotherapy or with poorly controlled HIV need a low threshold for swab, oral therapy and admission. Recurrence is the rule rather than the exception unless underlying immunosuppression is reviewed and skin barrier disease is controlled.

Athletes and contact sports

Wrestlers, rugby players and grapplers should be excluded from training and competition until lesions have crusted and at least 72 hours of antibiotic therapy has been completed in many sport-specific guidelines. Coordinate with team medical and athletic-training services and screen close team-mates when an outbreak is suspected.

Outbreak settings

Schools, daycare centres, prisons, dialysis units and military barracks need coordinated screening, lesion covering, environmental cleaning and—where culture or epidemiology supports—decolonisation programmes. Notify infection prevention and public-health colleagues early; share case definitions and a single contact for queries.

• Treatment failure clock: reassess at day 5–7. Persistent or worsening lesions usually mean wrong diagnosis or non-adherence—reorder the differential before escalating antibiotics.
• Allergy stewardship: document the allergy story carefully; many self-reported "penicillin allergies" are non-IgE rashes that would tolerate cephalexin or flucloxacillin under supervision and are far better than defaulting to clindamycin or macrolides.
• Antimicrobial stewardship: hydrogen peroxide first for localised disease where guidelines recommend, no extended courses, single-agent therapy, culture-led step-up where possible. Five-day topical and 7-day oral are usual; do not exceed without microbiology rationale.
• Infection prevention bundle: covered lesions, dedicated towels and razors, hot-wash bedding and clothing, separate sleeping arrangements while contagious, structured aseptic technique for any wound care, environmental cleaning of high-touch surfaces, and hand hygiene reminders for everyone in the household.
• Wound care reality: topical therapy works only if the crust is gently soaked off first; document a wound-care plan via wound care and use clean wound irrigation with saline or tap water before the next dose.
• Medication safety on the ward: reconcile community antibiotics with hospital stocks via structured medication reconciliation, double-check paediatric weight-based dosing using safe medication administration, and monitor for clindamycin-associated C. difficile when prolonged courses are unavoidable.
• School and daycare exclusion: at least 24 hours of antibiotic therapy plus covered lesions in most US/UK pathways; longer exclusion (until lesions are dry and crusted) when antibiotics are not used. Provide a written letter where required.
• Documentation discipline: record lesion count, distribution, depth, treatment chosen, infection-control plan, follow-up date and the carer or athlete who needs to know about the contagious window in a single line for next-shift handover.
• Safeguarding lens: when the lesion pattern, history or social context does not fit, consider neglect, abuse or factitious disease in both children and adults, and escalate via the local pathway.

Vital signs and surveillance

• Temperature at every encounter; new fever signals systemic spread or invasive disease.
• Blood pressure and resting peripheral pulse—watch for the post-streptococcal glomerulonephritis pattern (raised BP, oedema, oliguria) at follow-up appointments.
• Capillary refill, mottling and lethargy in infants—escalate per institutional pathway and trigger paediatric input early.
• Daily lesion size, count and crust character documented in the chart; mark expansion margin with surgical pen during inpatient care.

Targeted assessment

• Pain and itch with structured pain assessment (FLACC for infants, numerical rating in older children and adults); rising pain suggests deeper infection or HSV.
• Hydration, oral intake and feeding in infants with bullous disease.
• Comprehensive head-to-toe assessment at admission and any clinical change—look for missed lesions in scalp, axillae, groin and intertriginous folds.
• Skin barrier markers: dryness, lichenification, scratch marks, scabies burrows—these drive recurrence and need their own treatment plan.

Infection control essentials

• Standard plus contact precautions until lesions have dried out or 24–48 hours of antibiotic therapy have elapsed.
• Dedicated towels, washcloths, razors and bedding for the affected person; hot-wash linen and clothing; bag and discard contaminated dressings as clinical waste.
• Cohort management when outbreaks occur; brief environmental cleaning of door handles, bath toys and shared surfaces.
• Educate carers and patients on the "don’t pick, don’t share, don’t scratch" rule.

Red flags requiring escalation

• Rapid expansion of erythema beyond the lesion margin, induration, lymphangitic streak.
• Fever with tachycardia or lethargy out of proportion to the local lesion.
• New oral mucosal sloughing, generalised erythema or Nikolsky-positive skin (suspect SSSS).
• Pain disproportionate to lesion appearance; crepitus or dusky skin (necrotising soft-tissue infection).
• Periorbital oedema, dark urine or rising blood pressure 1–5 weeks after the rash (post-streptococcal GN).

Local

• Autoinoculation to other body sites; new lesions appearing during the same illness.
• Ecthyma with deep ulceration and scarring.
• Post-inflammatory hyperpigmentation, especially in patients with darker skin; counsel on slow normalisation over months.
• Secondary bacterial cellulitis with deeper-tissue spread; warmth, oedema and tenderness over a wider area.

Systemic

• Bacteraemia and sepsis—particularly in neonates, immunocompromised and ecthyma cases.
• Staphylococcal scalded skin syndrome in young infants.
• Pneumonia, septic arthritis or osteomyelitis from haematogenous spread of S. aureus—rare but high-stakes when missed.
• Toxic shock syndrome with shock, multi-organ involvement and desquamation—medical emergency.

Post-streptococcal complications

• Acute post-streptococcal glomerulonephritis: 1–5 weeks after streptococcal impetigo, more common in some endemic settings; presents with cola urine, periorbital oedema, hypertension and oliguria. Refer to paediatrics or nephrology promptly; supportive care with sodium and fluid restriction, antihypertensives, and close surveillance.
• Acute rheumatic fever does not follow streptococcal impetigo (only pharyngitis); reassure clinicians who panic on this point but stay alert to coexistent untreated pharyngitis.
• Reactive arthritis and psoriasis-guttate flares are less common but described.

Most prevention is barrier care plus contact-and-fomite control. Key clinician-modifiable strands: keep skin barrier intact (emollients in atopic dermatitis, treat scabies and lice promptly), clean cuts and abrasions with soap and water, cover wounds in sport and high-risk work, and avoid sharing towels, razors and athletic gear.

Recurrent disease

• Treat any underlying skin condition aggressively and completely.
• Take nasal swabs for S. aureus carriage; consider screening household contacts.
• Five-day decolonisation regimen: intranasal mupirocin twice daily, daily chlorhexidine 4% body wash or dilute bleach baths (12.5 mL household bleach in a half-full standard bath), nail-trimming and antiseptic skin care—rotate with infectious-disease guidance to avoid mupirocin resistance.
• Wash bedding, towels, sportswear and soft toys at high temperature; replace toothbrushes and razors after the course.
• Educate athletes, school staff and carers on the contagious window and lesion covering.

Public health

In endemic, low-resource and tropical settings, mass drug administration with topical or oral azithromycin alongside scabies treatment has been shown to reduce community impetigo prevalence in cluster trials; deploy under public-health leadership, not opportunistically. Universal screening of asymptomatic children is not recommended outside outbreak management.

Uncomplicated impetigo is a short-course, low-mortality disease. With effective therapy, most lesions are visibly healing within 3–5 days and the contagious window collapses to 24–48 hours after treatment starts. Without treatment, around 20% of cases resolve spontaneously over 14–21 days; the rest persist or autoinoculate. Scarring is rare in nonbullous disease but expected in ecthyma. Post-inflammatory hyperpigmentation can persist for months, particularly in skin of colour. Long-term morbidity is dominated by missed post-streptococcal glomerulonephritis (a small proportion progressing to chronic kidney disease) and by recurrent disease tied to underlying atopic dermatitis or staphylococcal carriage.

Mortality is essentially confined to neonates with SSSS or sepsis, immunocompromised patients with invasive staphylococcal disease, and rare necrotising soft-tissue infections; vigilance for these phenotypes is the single most useful long-term outcome lever.

Subtle deterioration

The impetigo patient who deteriorates rarely arrives shouting. Watch for the slow drift: a lesion margin that has expanded by half a centimetre overnight, a temperature that has crept from 37.2 to 38.0 °C across two visits, a parent who reports the child "just isn’t quite right" and a previously playful toddler who is now refusing food. Document those soft signs; they are usually what change the antibiotic ladder before any single observation crosses a threshold.

Communication friction

Carers and athletes often need permission, not persuasion, to take the contagious window seriously. Frame exclusion as "48 hours of antibiotics, then back to school" rather than indefinite quarantine. Counter influencer-driven advice (essential oils as monotherapy, chronic topical antibiotic creams, refusal of any treatment in healthy children) with calm physiology rather than confrontation. Acknowledge that the rash is not the parent’s fault—reassurance unlocks adherence.

Bedside checklist

• Confirm the lesion pattern and document it in plain language anyone can read at handover.
• Audit the underlying skin barrier disease—is the eczema controlled? Have the burrows of scabies been treated? Has the varicella crusted?
• Cover lesions, run through hand-hygiene teaching, and put a written plan in the family’s hands before they leave the room.
• Set the day-7 follow-up explicitly; it is the single most reliable safety net for missed atypical disease.

Initial bundle: ABCDE primary survey; secure IV access; send blood cultures and full sepsis screen; mark and photograph lesion margins; isolate per institutional infection-control policy; start empirical antibiotics broad enough to cover MRSA and group A streptococcus (commonly IV vancomycin plus an antistaphylococcal beta-lactam such as cefazolin, ± clindamycin for toxin suppression in suspected toxic shock or invasive GAS) per local guideline; reconcile allergies and weight; involve infectious-disease, paediatric or critical-care teams without delay; document escalation through structured handoff at every transition of care.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, classic SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze completion on the topic of impetigo recognition, antibiotic selection, infection control and post-streptococcal surveillance—matched to Clinical Judgment Measurement Model reasoning that takes the candidate from cue recognition through evaluation of outcomes.